---
title: "KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286605213.md"
description: "KALA BIO, Inc. reported a net loss of $(1.6M) in Q1 2026, an improvement from $(8.9M) in Q1 2025, with diluted EPS at $(0.14) compared to $(70.49) a year prior. The company is pivoting to an AI platform for biotech and pharma, focusing on asset monetization and operational cost reductions, including ceasing KPI-012 development. They have also executed a licensing agreement for the Researgency Platform."
datetime: "2026-05-15T19:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286605213.md)
  - [en](https://longbridge.com/en/news/286605213.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286605213.md)
---

# KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary

KALA BIO, Inc. reported a smaller net loss in the first quarter of 2026, recording a net loss attributable to common stockholders of $(1.6M) compared with a $(8.9M) loss in the year‑ago quarter; diluted net loss per share was $(0.14) versus $(70.49) in Q1 2025.

**Financial Highlights**

-   Net income: Net loss attributable to common stockholders of $(1.6M) for Q1 2026, improved from a net loss of $(8.9M) in Q1 2025.
-   Diluted EPS: Diluted net loss per share of $(0.14) for Q1 2026, versus $(70.49) in Q1 2025.

**Business Highlights**

-   Strategic pivot to AI platform: The company shifted from MSC-S biologics to developing and commercializing an on‑premises Researgency AI platform targeted at biotech and pharma customers.
-   Asset monetization focus: KALA BIO is pursuing licensing, collaborations or sales for KPI‑012, KPI‑014 and related intellectual property to preserve value from prior biologics programs.
-   Operational cost reduction: The company ceased KPI‑012 development and significantly reduced R&D and G&A headcount and expenses to align with the new AI strategy.
-   Partnerships and licensing milestone: Executed an exclusive license and development agreement for the Researgency Platform that includes deliverables, equity and an option to acquire the licensor.

Original SEC Filing: KALA BIO, Inc. \[ KALA \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KALA.US](https://longbridge.com/en/quote/KALA.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)